Medivation Company Profile (NASDAQ:MDVN)

Analyst Ratings

Consensus Ratings for Medivation (NASDAQ:MDVN) (?)
Ratings Breakdown: 1 Sell Rating(s), 7 Hold Rating(s), 13 Buy Rating(s)
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $72.90 (16.40% upside)

Analysts' Ratings History for Medivation (NASDAQ:MDVN)
Show:
DateFirmActionRatingPrice TargetActions
7/17/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Credit Suisse Group AGReiterated RatingBuy$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016WedbushReiterated RatingOutperform$63.00 -> $66.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/7/2016BMO Capital MarketsReiterated RatingMarket Perform$50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/7/2016Leerink SwannReiterated RatingMarket Perform$64.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/7/2016Jefferies GroupReiterated RatingHold$56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Barclays PLCReiterated RatingOverweight$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2016Royal Bank Of CanadaReiterated RatingSector Perform$40.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2016Brean CapitalReiterated RatingBuy$61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Maxim GroupBoost Price TargetBuy$47.00 -> $76.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016MizuhoDowngradeNeutral -> Underperform$150.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Stifel NicolausBoost Price TargetBuy$52.00 -> $66.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/1/2016Goldman Sachs Group Inc.Reiterated RatingNeutral$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016SunTrust Banks Inc.Reiterated RatingBuy$56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/4/2016BTIG ResearchReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Bank of America Corp.Initiated CoverageBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/31/2016William BlairReiterated RatingOutperform$83.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/26/2015JMP SecuritiesLower Price TargetMarket Outperform$152.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2015Nomura Holdings Inc.Initiated CoverageBuy$140.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2015JPMorgan Chase & Co.Boost Price TargetOverweight$130.00 -> $148.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2014AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/12/2014Chardan CapitalBoost Price TargetBuy$100.00 -> $122.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2014Sanford C. BernsteinUpgradeMarket Perform -> Outperform$118.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Keefe, Bruyette & WoodsReiterated RatingOutperform$104.00 -> $107.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Medivation (NASDAQ:MDVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116$0.23$0.11$197.01 million$182.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415$0.25$0.29$373.85 million$377.74 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$0.33$0.35$236.70 million$260.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215$0.45$0.58$155.22 million$175.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115$0.27$0.17$149.00 million$129.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2015Q414$1.33$1.96$233.19 million$274.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314$0.84$0.96$182.00 million$200.48 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214$0.24$0.60$126.46 million$148.09 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.09)($0.18)$94.64 million$87.19 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.08)$0.03$72.68 million$96.61 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/30/2014Q4($0.14)($0.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q313($0.26)($0.18)$60.13 million$108.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.21)($0.07)$59.35 million$70.15 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.45)($0.36)$38.54 million$46.15 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2013Q4 2012($0.52)($0.43)$34.36 million$37.16 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312($0.03)($0.06)$52.11 million$64.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2012$0.23($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012$1.19$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2012($0.25)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2011($0.31)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2011($0.25)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2011($0.24)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2011($0.17)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Medivation (NASDAQ:MDVN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20165$0.18$0.26$0.22
Q3 20162$0.30$0.31$0.31
Q4 20162$0.34$0.42$0.38
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Medivation (NASDAQ:MDVN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Medivation (NASDAQ:MDVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016Andrew Kenneth William PowellSVPSell2,578$60.42$155,762.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2016Rick BierlyCFOSell10,340$59.76$617,918.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Dawn SvoronosDirectorSell6,000$38.90$233,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016David HungCEOSell5,085$41.10$208,993.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Mohammad HirmandInsiderSell1,525$41.10$62,677.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Rick BierlyCFOSell2,998$40.00$119,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2016David HungCEOSell6,350$31.18$197,993.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Clarence Patrick MachadoDirectorSell75,000$37.34$2,800,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Joseph M LobackiInsiderSell3,065$46.50$142,522.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2015W Anthony VernonDirectorBuy15,000$40.69$610,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015David HungCEOSell10,950$43.10$471,945.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Mohammad HirmandInsiderSell1,075$43.40$46,655.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Clarence Patrick MachadoDirectorSell71,980$42.36$3,049,072.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Dawn SvoronosDirectorSell3,100$89.15$276,365.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Clarence Patrick MachadoDirectorSell36,000$117.43$4,227,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Rick BierlyCFOSell1,000$130.00$130,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2015Rick BierlyCFOSell1,615$125.00$201,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2015Rick BierlyCFOSell2,170$124.70$270,599.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Rick BierlyCFOSell3,000$132.20$396,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Jennifer J RhodesInsiderSell1,390$130.92$181,978.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015David HungCEOSell100,891$120.83$12,190,659.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Dawn SvoronosDirectorSell3,350$119.75$401,162.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Jennifer J RhodesInsiderSell2,000$122.00$244,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2015Kathryn E FalbergDirectorBuy25,000$117.67$2,941,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2015David HungCEOSell19,109$120.12$2,295,373.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2015Jennifer J RhodesInsiderSell3,089$119.29$368,486.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015David HungCEOSell3,190$100.48$320,531.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015Clarence Patrick MachadoDirectorSell36,000$105.32$3,791,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015David HungCEOSell100,000$108.14$10,814,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014Clarence Patrick MachadoDirectorSell1,580$113.00$178,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014David HungCEOSell5,420$113.00$612,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Lynn SeelyInsiderSell55,000$98.47$5,415,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Lynn SeelyInsiderSell20,000$94.60$1,892,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Lynn SeelyInsiderSell20,000$89.42$1,788,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Lynn SeelyInsiderSell20,000$83.62$1,672,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Lynn SeelyInsiderSell25,500$83.02$2,117,010.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2014Lynn SeelyInsiderSell7,500$73.96$554,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2014Lynn SeelyInsiderSell12,000$79.02$948,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Lynn SeelyInsiderSell15,000$74.75$1,121,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Clarence Patrick MachadoCFOSell40,000$82.79$3,311,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Clarence Patrick MachadoCFOSell40,000$80.83$3,233,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Clarence Patrick MachadoCFOSell40,000$73.46$2,938,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2014Clarence Patrick MachadoCFOSell40,000$75.43$3,017,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2014David HungCEOSell150,000$73.50$11,025,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Clarence Patrick MachadoCFOSell40,000$76.29$3,051,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Jennifer RhodesInsiderSell14,000$76.28$1,067,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2013Clarence Patrick MachadoCFOSell5,425$62.66$339,930.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2013David HungCEOSell15,050$62.61$942,280.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2013Cheryl CohenInsiderSell50,000$64.25$3,212,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/2/2013Cheryl CohenInsiderSell25,000$59.31$1,482,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2013David HungCEOSell30,885$55.45$1,712,573.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Cheryl CohenInsiderSell25,000$54.01$1,350,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/4/2012David HungCEOSell50,000$57.92$2,896,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Medivation (NASDAQ:MDVN)
DateHeadline
07/24/16 04:43 PMIs $76 Price Target Attainable For Medivation, Inc. (NASDAQ:MDVN)? - Investor Newswire
07/24/16 09:25 AMHC Stocks Zone: Zoetis Inc (NYSE:ZTS), Medivation Inc (NASDAQ:MDVN) - share market updates (press release)
07/24/16 09:25 AMAnalytical Approach on Price Target Estimates: Medivation Inc (NASDAQ:MDVN) - Post Registrar
07/21/16 05:22 PMHow Fast Can This Stock Grow - Medivation, Inc. (NASDAQ:MDVN) - TGP
07/21/16 05:22 PMLooking At Recent Analyst Ratings: Medivation Inc (NASDAQ:MDVN), Tripadvisor Inc (NASDAQ:TRIP) - Review Fortune
07/21/16 05:22 PMMedivation, Inc. (NASDAQ:MDVN): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 05:22 PMStock Catching Eyes of Investors: Medivation, Inc. (NASDAQ:MDVN) - TGP
07/21/16 05:22 PMBroker Outlook For Medivation, Inc. (NASDAQ:MDVN) - Fiscal Standard
07/20/16 02:00 PMSix Major Biotech Acquisitions You Could See in 2016 (Part 1 of 3) -
07/19/16 10:58 AMStock Positive on the Year: Medivation, Inc. (NASDAQ:MDVN) - TGP
07/19/16 10:58 AMLong Term Value Play: Medivation, Inc. (NASDAQ:MDVN) - TGP
07/18/16 10:25 AMHC Stocks Summary: Medivation Inc (NASDAQ:MDVN) Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) - share market updates (press release)
07/17/16 04:36 PMStrong Sell Calls For Medivation, Inc. (NASDAQ:MDVN) At 0 - Investor Newswire
07/17/16 09:27 AMWere Analysts Bearish Medivation Inc (NASDAQ:MDVN) This Week? - Consumer Eagle
07/17/16 09:27 AMIguana Healthcare Management LLC Increased Medivation INC (NASDAQ:MDVN) by $9.31 Million as Shares Declined - Press Telegraph
07/17/16 09:27 AMShare Performance Summary for: Medivation, Inc. (NASDAQ:MDVN) - Press Telegraph
07/15/16 09:32 AMInstitutions are Increasing Positions in Medivation, Inc. (NASDAQ:MDVN) - Engelwood Daily
07/15/16 09:32 AMBiotech news that matter for investors: Medivation, Inc. (NASDAQ:MDVN), EPIRUS Biopharmaceuticals, Inc. (NASDAQ ... - The Voice Registrar
07/15/16 09:32 AMStock Performance to Track: Medivation, Inc. (NASDAQ:MDVN) - News Oracle
07/14/16 08:45 AMInvestor News: Medivation Inc (NASDAQ:MDVN) under Investigation
07/13/16 05:31 PMMedivation, Inc. (NASDAQ:MDVN) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/13/16 10:27 AMAstraZeneca Plans to Step into the Medivation Battle: a Threat for Sanofi? -
07/13/16 08:03 AMIntraday Active Biotech Stocks News: Medivation, Inc. (NASDAQ:MDVN), Cerus Corporation (NASDAQ:CERS) - The Voice Registrar
07/13/16 08:03 AMIs Medivation, Inc.(NASDAQ: MDVN), a large market cap stock a smart buy? - The Daily Leicester
07/12/16 09:31 AMWedbush Previews Medivation's Q2 Earnings, Sees Takeout In Mid- To High-$60 Range
07/12/16 09:31 AMAstraZeneca plc (NYSE:AZN) considering A $10 Billion Bid For Medivation Inc (NASDAQ:MDVN)
07/11/16 11:54 AMAstraZeneca mulling $10B bid for Medivation -
07/11/16 09:48 AMStock Performance Rundown on: Medivation, Inc. (NASDAQ:MDVN) - Press Telegraph
07/11/16 09:48 AMNext Weeks Broker Price Targets For Medivation, Inc. (NASDAQ:MDVN) - Fiscal Standard
07/09/16 04:41 PMA look at a High Market Cap Stock: Medivation, Inc., MDVN - The Daily Leicester
07/08/16 08:02 AMPrevious Trading Session Wrap-Up: Medivation, Inc. (NASDAQ:MDVN) - Press Telegraph
07/08/16 08:02 AMMedivation, Inc. (NASDAQ:MDVN) from Biotechnology – Todays Top Gains - Twin County News
07/08/16 08:02 AMStock Analysis review: Medivation, Inc. (NASDAQ:MDVN) - News Oracle
07/07/16 05:11 PMMedivation, Inc. | $MDVN Stock | Shares Tick Up On Announcement of Confidentiality Agreements - Warrior Trading News (press release)
07/07/16 05:11 PMStock Setting a Recent High: Medivation, Inc. (NASDAQ:MDVN) - Press Telegraph
07/07/16 05:11 PMEarnings Preview: Jefferies Weighs In on Gilead Sciences, Inc. (GILD), Medivation Inc (MDVN) and Amarin Corporation ... - Smarter Analyst
07/07/16 08:00 AMMedivation Inc. (MDVN) is Trading Higher on Unusual Volume for July 05 - Equities.com
07/07/16 08:00 AMHow has Medivation, Inc.:(NASDAQ:MDVN) performed recently? - The Daily Leicester
07/06/16 05:20 PMStock Strength Recap for Medivation, Inc. (NASDAQ:MDVN) - Press Telegraph
07/06/16 05:20 PMTop Gainers of the Day: Medivation, Inc. (NASDAQ:MDVN) from Biotechnology - Twin County News
07/06/16 05:20 PMRecommendation Trends for Investors: Medivation, Inc. (NASDAQ:MDVN) - News Oracle
07/06/16 05:20 PMMedivatio, Inc. (MDVN) Enters into Confidentiality Agreements, Including with Sanofi - ValueWalk
07/06/16 05:03 PMCancer drug discovered by UCLA sets off takeover fight among biotech companies - A high-priced prostate cancer drug discovered at UCLA is at the center of a multibillion-dollar takeover battle that has several giant pharmaceutical firms eyeing the purchase of San Francisco biotech firm Medivation. Medivation sells the drug Xtandi for about $129,000 a year. Earlier this year, two...
07/06/16 01:43 PMMedivation Tells Big Pharma to Begin Bidding War - After rejecting multiple offers, Medivation's board finally appears to be open to selling.
07/06/16 09:47 AMMedivation Reaches Confidentiality Agreements, Incl. With Sanofi
07/06/16 09:47 AMSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Medivation, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
07/06/16 09:47 AMBuzz Stocks: Walgreens Boots Alliance Inc, Medivation Inc, and Tesla Motors Inc
07/06/16 09:20 AMDo Confidentiality Agreements Signal an Impending Medivation Acquisition? -
07/05/16 04:58 PMMedivation Inc. (MDVN) Is Climbing On Takeover Interest - RTT News
07/05/16 04:25 PM[$$] Sanofi, Medivation Start Takeover Talks -

Social

About Medivation

Medivation logoMedivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MDVN
  • CUSIP: 58501N10
Key Metrics:
  • Previous Close: $62.63
  • 50 Day Moving Average: $60.49
  • 200 Day Moving Average: $48.37
  • P/E Ratio: 42.06
  • P/E Growth: 1.38
  • Market Cap: $10.31B
  • Beta: 0.9
  • Current Year EPS Consensus Estimate: $1.29 EPS
  • Next Year EPS Consensus Estimate: $2.20 EPS
Additional Links:
Medivation (NASDAQ:MDVN) Chart for Sunday, July, 24, 2016